Cardinal Health (NYSE:CAH) reported strong Q2 Fiscal Year 2026 earnings, beating expectations with an EPS of $2.63. The company saw broad-based performance across all segments, with significant growth in pharmaceutical and specialty solutions, and continued progress in its GMPD turnaround. Cardinal Health raised its fiscal year 2026 earnings per share guidance to a new range of $10.15 to $10.35, reflecting confidence in its strategic execution and strong market demand.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cardinal Health, Inc. (NYSE:CAH) Q2 2026 Earnings Call Transcript
Cardinal Health (NYSE:CAH) reported strong Q2 Fiscal Year 2026 earnings, beating expectations with an EPS of $2.63. The company saw broad-based performance across all segments, with significant growth in pharmaceutical and specialty solutions, and continued progress in its GMPD turnaround. Cardinal Health raised its fiscal year 2026 earnings per share guidance to a new range of $10.15 to $10.35, reflecting confidence in its strategic execution and strong market demand.